Skip to main content

Polymyxin B-direct hemoperfusion therapy could contribute to hemodynamics and outcomes in emergency surgical patients


Polymyxin B-direct hemoperfusion (PMX-DHP) (Toraymyxin®; Toray Medical Co., Tokyo, Japan) has been approved to treat patients with endotoxemia and/or severe sepsis due to Gramnegative infection since 1994 in Japan. However, its efficacy and indication are still controversial. Recently, randomized controlled studies were performed in other countries. Our hypothesis is that PMX-DHP may be useful for emergency-operated patients to eliminate endotoxins from the systemic circulation after removal of the source of infection.


From July 1994 to May 2011, all adult patients treated with PMX-DHP in our ICU were included in this retrospective observational study. Patients' clinical and microbiological data were collected from medical archives. The emergency postoperation patients and the medical patients were compared for severity, mortality, and hemodynamic status. Values are expressed as mean ± SD. Data were analyzed by Mann-Whitney U test, chi-square test and Fisher's exact probability test. P < 0.05 was considered statistically significant.


One hundred and sixty-six patients (98 men, 68 women; age range 24 to 92 years (mean 64.7 ± 13.3)) were studied. The mortality rate was 34.9% at 28 days after PMX-DHP. There were 129 (77.7%) emergency surgical patients and 37 (22.3%) medical patients. The APACHE II score on the day of PMX-DHP was not significantly different between surgical and medical patients (20.3 ± 7.0 vs. 19.2 ± 8.1, P = 0.417). Mean arterial pressure (MAP) significantly improved in emergency surgical patients before and after PMX-DHP therapy (73.7 ± 24.8 vs. 79.7 ± 26.0 mmHg, P = 0.017), while MAP was not statistically different in medical patients (69.7 ± 24.2 vs. 76.7 ± 27.1 mmHg, P = 0.178). The inotropic score had no statistical difference between before and after PMX-DHP in both surgical and medical patients (13.2 ± 19.8 vs. 12.6 ± 19.2, P = 0.61; 16.8 ± 27.3 vs. 13.8 ± 23.6, P = 0.65, respectively). The mortality rates at 28 days, 90 days, 0.5 year and 1 year after PMX-DHP were significantly different between surgical and medical patients (28.7 vs. 56.8, 43.8 vs. 83.3, 52.2 vs. 85.7, 54.5 vs. 91.2%, P < 0.0001, respectively).


MAP increased in surgical patients but did not change in medical patients after PMX-DHP, and the inotropic score was not significantly different in both sets of patients. The mortality was significantly lower in surgical patients than in medical patients.

Author information



Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Cite this article

Yokota, M., Goto, T., Harada, T. et al. Polymyxin B-direct hemoperfusion therapy could contribute to hemodynamics and outcomes in emergency surgical patients. Crit Care 16, P382 (2012).

Download citation

  • Published:

  • DOI:


  • Severe Sepsis
  • Mean Arterial Pressure
  • Surgical Patient
  • Medical Patient
  • Polymyxin